-
-
Toggle navigation
The 5th most cited journal in Immunology
in Immunology |
|
Submit your manuscript
Scope
The section deals with disorders due to immune-mediated injury of the central (CNS) and peripheral (PNS) nervous systems. There are recognized diseases that are neuroimmune. There are also a number of disorders, such as neurologic infections, neurodegenerative diseases, and systemic autoimmune/connective tissue/inflammatory conditions, that have critical neuroimmune components. Multiple sclerosis (MS) is given a special emphasis, because it is the chief immune-mediated disorder involving the CNS, a major disorder of young adults, and serves as the premier therapeutic success story in modern neurology. Other disorders include CNS inflammatory conditions, such as acute disseminated encephalomyelitis/postinfectious encephalomyelitis, neuromyelitis optica-devic spectrum, transverse myelitis, optic neuritis, PANDAS, and Stiff Person syndrome. PNS disorders include Guillain Barre syndrome, the immune-mediated neuropathies, myasthenia gravis, Lambert Eaton myasthenic syndrome, poly/dermatomyositis, and inclusion body myositis. Systemic processes that have neuroimmune components include paraneoplastic syndromes, Behcets disease, sarcoidosis, vasculitis, systemic lupus erythematosis , and related disorders.Optimum diagnosis and management of these disorders is predicated on a better understanding of how the nervous system participates in and responds to the immune system. The nervous and immune systems, along with the endocrine system, form an intercommunicating network that is an increasing focus of study.
Multiple Sclerosis and Neuroimmunology is dedicated to improving basic and clinical knowledge on how the nervous, immune and endocrine systems interact, and how those interactions can result in disease. The goal is to advance knowledge and ultimately clinical care in this area. We invite both clinical and basic science articles in this unique area of expanding interest.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), EMBASE, Semantic Scholar, Ulrich's Periodicals Directory, CLOCKSS, EBSCO, OpenAIRE, Zetoc
PMCID: all published articles receive a PMCID
Multiple Sclerosis and Neuroimmunology welcomes submissions of the following article types: Case Report, Classification, Clinical Study Protocol, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review and Systematic Review.
All manuscripts must be submitted directly to the section Multiple Sclerosis and Neuroimmunology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Multiple Sclerosis and Neuroimmunology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Neurology and Immunology.
Frontiers Editorial Office
EPFL - Innovation Square, Building I
CH – 1015 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
EPFL - Innovation Square, Building I
CH – 1015 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01